- Therapeutic Cataract & Refractive
- Lens Technology
- Glasses
- Ptosis
- Comprehensive Eye Exams
- AMD
- COVID-19
- DME
- Ocular Surface Disease
- Optic Relief
- Geographic Atrophy
- Cornea
- Conjunctivitis
- LASIK
- Myopia
- Presbyopia
- Allergy
- Nutrition
- Pediatrics
- Retina
- Cataract
- Contact Lenses
- Lid and Lash
- Dry Eye
- Glaucoma
- Refractive Surgery
- Comanagement
- Blepharitis
- OCT
- Patient Care
- Diabetic Eye Disease
- Technology
This week in optometry: December 11-December 15
Catch up on what happened in optometry during the week of December 11-December 15.
Catch up with what Optometry Times® shared this week:
FDA approves iDose TR from Glaukos for reduction of IOP and ocular hypertension
David Hutton, Managing Editor, Ophthalmology Times
iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has received FDA approval following a new drug application (NDA) submission.
Parental perspectives on myopia unveiled by The Vision Council
Emily Kaiser Maharjan, Assistant Managing Editor
A research report compiled by The Vision Council reveals that most parents are aware of myopia but remain in the dark about prevalence and how to prevent progression.
New tools emerge for the early detection of hydroxychloroquine maculopathy
Kyra Dorgeloh, OD, FAAO; Leena Walker, OD, FAAO
Hydroxychloroquine is considered to have a favorable systemic safety profile, even for long-term use, but poses the risk for retinal toxicity and irreversible vision loss.
Topline results from Ersa Phase 2a trial revealed by Tarsus
Martin David Harp, Associate Editor, Ophthalmology Times
TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.
2023 in review: A review of FDA approvals in eye care this year
Martin David Harp, Associate Editor, Ophthalmology Times; Emily Kaiser Maharjan, Assistant Managing Editor
Eye care witnessed a transformative year with 11 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.
